Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 2/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27047057 | 0.77 | CRBN (0.38) | SMN1; SMN2CRBNTOP2ATOP2BALDH1A1 | |
| SCHEMBL5449273 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2CRBN | |
| SCHEMBL19919507 | 0.74 | TOP2A (0.38) | SMN1; SMN2CRBNTOP2ATOP2BALDH1A1 | |
| SCHEMBL21847510 | 0.73 | — | — | |
| SCHEMBL19280067 | 0.73 | SMN1; SMN2 (0.35) | SMN1; SMN2CRBN | |
| SCHEMBL22445809 | 0.73 | SMN1; SMN2 (0.35) | SMN1; SMN2CRBN | |
| SCHEMBL17191409 | 0.70 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL2555704 | 0.70 | — | — | |
| SCHEMBL27775974 | 0.68 | NR1H2 (0.33) | — | |
| SCHEMBL2995460 | 0.68 | SMN1; SMN2 (0.48) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | SMN1; SMN2 4014/4885CRBN 4426/4885TOP2A 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.